Avid Bioservices Inc (CDMO)

[cjgaddy]

Dr. Eric J. Lawitz, Alamo Medical Research

We know about Godofsky & Bach (the largest private infectious disease practice specializing in the treatment of viral hepatitis in the USA). Now, more on AMR & Dr. Lawitz:

Alamo Medical Research (AMR), is an organization dedicated to clinical research... We utilize Central IRBs for rapid approvals. We routinely get projects started, enrolling and subject's treatment initiated months before university-based researchers. We have met all enrollment targets and are frequently the leading enroller for multi-centered trials. We have a fully qualified and experienced professional, research and support staff. Our mission focus is on delivering the highest quality of products and services to our sponsors and facilitating access to the latest and most innovative clinical trials to our community. AMR is co-located and associated with Digestive Diseases Center of South Texas, a multi-physician gastroenterology practice which provides a steady source of potential subjects... AMR has specialized in gastroenterology and chronic Hepatitis C since 1994. Given our ability to be high enrollers, we had many sponsor targeted audits and have consistently received complementary reviews.
Sponsors we have worked with include:
• Schering-Plough Research Institute
• Novartis Pharmaceuticals Corp
• Intermune Inc.
• Idenix Pharmaceuticals
• Vertex Pharmaceuticals
• Akros Laboratories
• Anadys Pharmaceuticals Inc.
• Guilford Laboratories
• Coley Pharmaceutical Group
• Glaxo Smith Kline Group
• TAP Pharmaceuticals
• MGI Pharma
• Roche Laboratories
Dr. Eric J. Lawitz is board certified in Gastroenterology and Internal Medicine and is the director and principal investigator for AMR. Dr. Lawitz has been conducting clinical trials for 11 years, has conducted extensive research in Chronic Hepatitis C and is a Certified Clinical Research Investigator. He has been both an investigator and sponsor/investigator. Dr. Lawitz has extensive experience in Internal Medicine and Gastroenterology.
http://www.alamomedicalresearch.com
http://www.centerwatch.com/professional/pro1738.html

LAWITZ NOTES:
1. Dr. Eric Lawitz was the lead author of Vertex’s Ph.2 28-day “VX-950 + pegIFN + RBV” trial, encouraging results of which were announced 5-21-06:
http://www.vrtx.com/Pressreleases2006/pr052106.html
2. Dr. Lawitz has received research grants to conduct investigator-initiated research from Schering-Plough Corp.
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=539356
3. Dr. Lawitz co-authored Idenix’s prelim. Ph.IIa NM283 results at EASL2005, with N Afdhal, M Rodriguez-Torres, E Lawitz, E Godofsky, G Chao, B Fielman, S Knox, N Brown
http://www.natap.org/2005/EASL/easl_8.htm
4. Dr. Lawitz co-authored Corley’s Ph.I CPG 10101 (Actilon) results at DDW2006, with J. McHutchison [PPHM SRB (Duke)], R. Ghalib, E. Lawitz, and others.
http://www.hivandhepatitis.com/2006icr/ddw/docs/060606_b.html

= = = = = =
6-7-06 PR: HepC Single-Dose Ph1a Efficacy Data – 'Promising Anti-Viral Activity'
”DOSING HAS BEGUN IN A NEW PH. IB HCV REPEAT DOSE STUDY"
...at 2 sites: Bach&Godofsky (PI Dr. Eliot Godofsky) & Alamo Medical Res./San Antonio (PI Dr. Eric Lawitz)
http://www.investorshub.com/boards/read_msg.asp?message_id=11471402

HEP-C REPEAT-DOSE Trial protocol (init. 6-2006): http://clinicaltrials.gov/ct/show/NCT00343525